An observational multi‐clinic implementation science study to evaluate barriers and enablers of real‐world use of confirmatory blood‐based biomarkers for the diagnosis of early Alzheimer’s disease
Leah Zullig, Soeren Mattke, Jo Vandercappellen, Daryl Jones, Harald Hampel, Richard Batrla · 2025
Read An observational multi‐clinic implementation science study to evaluate barriers and enablers of real‐world use of confirmatory blood‐based biomarkers for the diagnosis of early Alzheimer’s disease by Leah Zullig, Soeren Mattke, Jo Vandercappellen, Daryl Jones, Harald Hampel, Richard Batrla (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716053.txt.
Description
Leah Zullig and five co-authors set out a study plan for learning what helps or blocks the real world use of blood tests that confirm Alzheimer's disease, in this 2025 paper. Blood tests can now verify amyloid in the brain about as well as spinal fluid tests or tracer scans. Yet new tools often sit unused for years because clinics face practical barriers.
The plan covers several clinics and patients referred for worsening thinking problems. One group follows standard care, where scans or spinal tests confirm the diagnosis. The other uses the blood test instead. Surveys and interviews with doctors and patients will gauge whether the test is welcome, workable, and fair in who it reaches. The results should show what clinics must change to adopt the tests.
Catalog record
| CREATOR | Leah Zullig, Soeren Mattke, Jo Vandercappellen, Daryl Jones, Harald Hampel, Richard Batrla |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |